JP2004538319A5 - - Google Patents

Download PDF

Info

Publication number
JP2004538319A5
JP2004538319A5 JP2003518438A JP2003518438A JP2004538319A5 JP 2004538319 A5 JP2004538319 A5 JP 2004538319A5 JP 2003518438 A JP2003518438 A JP 2003518438A JP 2003518438 A JP2003518438 A JP 2003518438A JP 2004538319 A5 JP2004538319 A5 JP 2004538319A5
Authority
JP
Japan
Prior art keywords
nsaid
flurbiprofen
ester
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003518438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004538319A (ja
Filing date
Publication date
Priority claimed from US10/186,371 external-priority patent/US20030027867A1/en
Application filed filed Critical
Publication of JP2004538319A publication Critical patent/JP2004538319A/ja
Publication of JP2004538319A5 publication Critical patent/JP2004538319A5/ja
Withdrawn legal-status Critical Current

Links

JP2003518438A 2001-06-29 2002-07-01 抗−hiv治療のためのr−nsaid化合物の用途 Withdrawn JP2004538319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30253301P 2001-06-29 2001-06-29
US10/186,371 US20030027867A1 (en) 2001-06-29 2002-06-28 Use of R-NSAID compounds for anti-HIV treatment
PCT/US2002/022289 WO2003013424A2 (en) 2001-06-29 2002-07-01 Use of r-nsaid compounds for anti-hiv treatment

Publications (2)

Publication Number Publication Date
JP2004538319A JP2004538319A (ja) 2004-12-24
JP2004538319A5 true JP2004538319A5 (enExample) 2006-01-05

Family

ID=26882034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518438A Withdrawn JP2004538319A (ja) 2001-06-29 2002-07-01 抗−hiv治療のためのr−nsaid化合物の用途

Country Status (6)

Country Link
US (1) US20030027867A1 (enExample)
EP (1) EP1420745A2 (enExample)
JP (1) JP2004538319A (enExample)
AU (1) AU2002322481A1 (enExample)
CA (1) CA2451691A1 (enExample)
WO (1) WO2003013424A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation A- (BETA) -42 DECREASING MEDICINAL PRODUCTS
WO2004032845A2 (en) * 2002-10-07 2004-04-22 Encore Pharmaceuticals, Inc. R-nsaid esters and their use
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
GB2475359A (en) * 2009-11-11 2011-05-18 Biocopea Ltd A compound for use in treating a fulminant respiratory disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091403A (en) * 1964-01-24 1967-11-15 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
FR1546478A (fr) * 1967-01-27 1968-11-22 Rhone Poulenc Sa Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0610141B2 (ja) * 1986-02-14 1994-02-09 新技術事業団 エイズウイルス性疾患処置剤
DE3824353A1 (de) * 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren
JPH0248526A (ja) * 1988-08-08 1990-02-19 Sumitomo Pharmaceut Co Ltd インドメタシン注射剤およびその製造方法
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
WO1993017680A1 (en) * 1992-03-13 1993-09-16 Sepracor, Inc. Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
DK169670B1 (da) * 1992-12-22 1995-01-09 Cheminova Agro As Fremgangsmåde til fremstilling af 2,3,5,6-tetrachlorpyridin
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5677469A (en) * 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
US5858738A (en) * 1996-11-07 1999-01-12 Merck & Co., Inc. Ermophilane sesquiterpenoids as HIV intergrase inhibitors
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
WO2000013684A2 (en) * 1998-09-03 2000-03-16 Loma Linda University Medical Center Pharmaceutical composition and method for treatment of inflammation
IN189741B (enExample) * 1998-11-09 2003-04-19 Council Scient Ind Res

Similar Documents

Publication Publication Date Title
JP2004538319A5 (enExample)
DK173585B1 (da) Anvendelse af alfa-liponsyre til fremstilling af et lægemiddel til bekæmpelse af sygdomme fremkaldt af retrovirus
RU2760682C2 (ru) Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции
KR101435242B1 (ko) 간염치료용 실리비닌 성분
CA2710605C (en) Anti - retroviral combination
JP2005515966A5 (enExample)
JP2015512406A5 (enExample)
JP2010525050A5 (enExample)
JP2011516613A5 (enExample)
JP2007532663A5 (enExample)
US8017652B2 (en) Activators of peroxisome proliferator-activated receptors
JP2017514911A5 (enExample)
CN108367001A (zh) 治疗丁型肝炎病毒感染
JP2009517411A5 (enExample)
WO2006092741A2 (en) Treatment of inflammatory disorders with praziquantel
JPS61286325A (ja) 後天的免疫不全症の治療剤
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
JP2008247822A (ja) 鎮痛用組成物
JPH04346930A (ja) 安定なアスピリン腸溶錠
JPH0352815A (ja) 血管内血液凝固症候群の治療剤
JP2004522780A5 (enExample)
CA2703918A1 (en) Solid pharmaceutical dosage forms of atazanavir and ritonavir combinations
WO2020029441A1 (zh) 尼克酰胺组合物在制备治疗索拉非尼手足皮肤反应药物中的应用
RU2120284C1 (ru) Комбинированное противовоспалительное, анальгезирующее, жаропонижающее средство
CN108135882A (zh) 包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物